The aim of this study was to answer the question whether quality of life and progression-free and overall survival are increased in adults with supratentorial malignant glioma who are treated with cytoreductive resection as compared with those who only undergo biopsy.
A literature search of the electronic databases MEDLINE, EMBASE, and CENTRAL was performed to identify relevant studies published before May 2008. Hand-searching of reference lists of the identified studies and relevant review articles was also performed. A study was considered eligible, regardless of study design (prospective or retrospective), if: 1) quality of life and/or progression-free and/or overall survival was compared among adult patients undergoing biopsy or resection, and 2) patient age and Karnofsky Performance Scale scores were not significantly different among the 2 groups compared.
One randomized controlled trial and 4 retrospective studies (involving a total of 1111 patients) were found eligible for this systematic review. A meta-analysis of the eligible studies demonstrated a significant increase in overall survival in the patients treated with resection instead of biopsy (hazard ratio 0.61, 95% CI 0.52–0.71, p < 0.0001, fixed-effect model). Although statistical pooling was not feasible, the available data suggest that quality of life was increased in patients treated with resection rather than biopsy, while there did not seem to be any significant difference in progression-free survival between the 2 groups.
Based on the best available evidence, it appears that cytoreductive resection in adults with supratentorial malignant glioma is associated with improved overall survival as compared with biopsy. However, well-designed prospective studies are needed for more solid conclusions to be drawn.
Abbreviations used in this paper: CENTRAL = Cochrane Central Register of Controlled Trials; HR = hazard ratio; ICP = intracranial pressure; KPS = Karnofsky Performance Scale; QOL = quality of life.
Address correspondence to: Abraham Tsitlakidis, M.D., M.Sc., First Department of Neurosurgery, AHEPA University Hospital, Aristotle University of Thessaloniki, Stilponos Kyriakidi 1, 54636, Thessaloniki, Greece. email:
Please include this information when citing this paper: published online September 11, 2009; DOI: 10.3171/2009.7.JNS09758.
AmmiratiMVickNLiaoYLCiricIMikhaelM: Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery21:201–2061987
ChangCHHortonJSchoenfeldDSalazerOPerez-TamayoRKramerS: Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer52:997–10071983
CurranWJJrScottCBHortonJNelsonJSWeinsteinASFischbachAJ: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst85:704–7101993
DeeksJJAltmanDGBradburnMJStatistical methods for examining heterogeneity and combining results from several studies in meta-analysis. EggerMDavey SmithGAltmanDG: Systematic Reviews in Health Care: Meta-Analysis in Contexted 2LondonBMJ Publication Group2001. 228–247
GreenSBByarDPWalkerMDPistenmaaDAAlexanderEJrBatzdorfU: Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. Cancer Treat Rep67:121–1321983
HegiMEDiserensACGodardSDietrichPYRegliLOstermannS: Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res10:1871–18742004
InoYZlatescuMCSasakiHMacdonaldDRStemmer-RachamimovAOJhungS: Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. J Neurosurg92:983–9902000
JaeckleKAEyreHJTownsendJJSchulmanSKnudsonHMBelanichM: Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol16:3310–33151998
JeremicBGrujicicDAntunovicVDjuricLStojanovicMShibamotoY: Influence of extent of surgery and tumor location on treatment outcome of patients with glioblastoma multiforme treated with combined modality approach. J Neurooncol21:177–1851994
ShapiroWRGreenSBBurgerPCMahaleyMSJrSelkerRGVanGilderJC: Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J Neurosurg71:1–91989
SimpsonJRHortonJScottCCurranWJRubinPFischbachJ: Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials. Int J Radiat Oncol Biol Phys26:239–2441993
VechtCJAvezaatCJvan PuttenWLEijkenboomWMStefankoSZ: The influence of the extent of surgery on the neurological function and survival in malignant glioma. A retrospective analysis in 243 patients. J Neurol Neurosurg Psychiatry53:466–4711990
WarnkePCKrethFWScheremetROstertagCB: Response to Drs. Simpson, et al.: Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group clinical trials. Int J Radiat Oncol Biol Phys29:2201994. (Letter)